Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
Biotech
Biogen advances Alzheimer’s tau program despite midphase miss
While the study failed to yield the hoped-for dose-response data, reductions in tau and cognitive benefits led Biogen to commit to a pivotal trial.
Nick Paul Taylor
May 14, 2026 8:35am
Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset
May 13, 2026 9:15am
Roche nabs European approval for second Alzheimer’s test
May 12, 2026 7:07am
Protective gene sent to the liver cleared brain amyloid in mice
May 8, 2026 1:15pm
GSK’s $700M Alector bet blows up with 2nd Alzheimer’s fail
Apr 30, 2026 5:15am
Fierce Pharma
Anti-amyloid Alzheimer's drugs show 'trivial' effects: report
Apr 16, 2026 11:36am
